The Effect of Pioglitazone on Neointima Volume and Inflammatory Markers
Status:
Completed
Trial end date:
2015-07-01
Target enrollment:
Participant gender:
Summary
People with diabetes mellitus are more prone to coronary heart disease, stroke, and
peripheral vascular disease, and diabetes mellitus has been regarded as an independent risk
factor for the progression of coronary artery disease. Several studies have been reported
that diabetes increased the risk of cardiovascular mortality in both men and women. With the
introduction of drug-eluting stents (DESs), the angiographic rates of restenosis at later
months have reduced dramatically in several studies. However, even with DESs, diabetic
patients showed increased rates of restenosis and late loss index compared with nondiabetic
patients. Diabetes has been considered to be a predictor of poor prognosis after percutaneous
coronary intervention with drug-eluting stents. Long-term clinical and angiographic outcomes
after percutaneous coronary intervention (PCI) with drug-metal stents (DESs) have been
demonstrated to be worse in diabetic patients compared with nondiabetic patients. In the era
of DESs, no study has demonstrated the clinical and angiographic outcomes in diabetic
patients after zotarolimus-eluting stent implantation by using intravascular ultrasound
(IVUS).
Pioglitazone is used in the treatment of diabetic patients. Thiazolidinediones increase
insulin sensitivity and show favorable effect on blood glucose levels and lipid profiles. The
effect of pioglitazone on neointima volume and inflammatory markers has not been compared in
prospective manner after zotarolimus-eluting stent implantation. The purpose of this
prospective, randomized, single blinded trial is to compare the effect of pioglitazone on
inflammatory markers and neointima volume by using IVUS in diabetic patients.